pembrolizumab,nivolumab,durvalumab,tislelizumab,sorafenib
beigene,bms,bayer,astrazeneca,merck
['tislelizumab', 'nivo', 'sorafenib', 'rationale-301', 'hcc', 'durva', 'pembro']
 rationale-301 phase-iii presented at lb36 positive, but only non-inferiority shown compared to sorafenib in 1st line #hcc tislelizumab: orr 14% 2.2 mpfs mos 15.9 mo in line with pembro 17mo, nivo 16.4mo, durva 16.6mo #livertwitter 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine